What is IBI-Ag?
Established in 2017, IBI-Ag operates at the intersection of biotechnology and sustainable farming. The company specializes in the discovery and development of advanced biological solutions designed to mitigate insect-related crop damage. By utilizing breakthrough fermentation technology, IBI-Ag produces highly efficient and selective bio-insect control agents that prioritize environmental safety without compromising on yield performance.
The firm's market position is defined by its commitment to low-cost, high-impact agricultural inputs. By enabling farmers to integrate these biological tools into their existing workflows, IBI-Ag addresses the growing global demand for sustainable crop protection. Its technology is engineered to be both scalable and adaptable, positioning the company as a critical player in the transition toward greener, more resilient agricultural practices.
How much funding has IBI-Ag raised?
IBI-Ag has raised a total of $16.1M across 2 funding rounds:
Other Financing Round
$6.1M
Series A
$10M
Other Financing Round (2025): $6.1M with participation from The Trendlines Group and Corteva Agriscience
Series A (2025): $10M led by Consensus Business Group, The Trendlines Group, Corteva Agriscience, and Iron Nation
Key Investors in IBI-Ag
Corteva Agriscience
A global leader in the agriculture business, Corteva focuses on seed and crop protection, providing advanced germplasm and digital solutions to optimize farm yields.
The Trendlines Group
An investment firm that incubates and supports innovation-based medtech and agrifood technologies, taking a hands-on approach to business building and technology development.
Iron Nation
A volunteer-driven organization comprised of leading entrepreneurs and investors dedicated to ensuring the continuity of early-stage Israeli startups during periods of crisis.
What's next for IBI-Ag?
With the recent influx of capital, IBI-Ag is poised to transition into a phase of rapid commercial expansion. The strategic focus will likely center on scaling production capacity to meet international demand and deepening its research pipeline to address a broader spectrum of agricultural pests. Furthermore, the involvement of major industry players suggests a potential for strategic partnerships that could streamline the distribution of its bio-insecticides across diverse geographic markets.
As the company moves forward, the emphasis will remain on maintaining the cost-effectiveness of its fermentation processes while navigating the regulatory requirements of global agricultural markets. The continued support from its investor base provides the necessary runway to refine its product portfolio and solidify its role as a leader in the next generation of crop protection technology.
